Replies to post #81529 on NanoViricides Inc (NNVC)

[BRIG_88]

This is nothing new….they have been doing it for years.

[I Need Help]

NewMoney. You do know that NNVC is a small cap, development stage (developmental), biotech.

Let me share with you this from Investopedia:

'Definition of Development Stage'
A company that is in a preliminary or early state of its corporate life. A development stage company is characterized by its focus on early-stage business activities such as, research and development, market research or construction of manufacturing facilities. Development stage companies are generally underfunded and likely to be on the lookout for sources of capital.

Investopedia explains 'Development Stage'
While development stage companies usually have limited revenues and earnings, the prospect of substantial profits in a few years time, makes them attractive investments for risk-tolerant investors. Early-stage companies that can successfully grow their business and graduate to the big leagues over a period of time, are likely to reward their shareholders well. Since a substantial portion of development stage companies fail, a diversified approach is necessary when investing in such companies.

Your post said the following:

I was wondering why they avoided talking about their revenues in their fluff PR, so I went and looked up their SEC filing.

Now I get the song and dance. They are a cash burning machine.

Business model: Burn cash, dilute stock, issue fluff PR about how great everything is and the magic snake oil is coming along nicely. Complain that mean people and short sellers are to blame for disastrous management.

Wait.....

Repeat.

I hope the Investopdedia article clears up why developmental companies, such as NNVC have no earnings (or very low earnings). This is very typical for developmental biotechs.

You said you looked up the SEC filing. I assume you meant the 10Q released today. Did you read it? I did. The company made all kinds of disclosures. I did not hear a song or see a dance.

Burning cash is what development stage biotechs do. Luckily for shareholders, NNVC has been very frugal concerning the rate of cash burn. That is one reason why after over 9 years, there are only approximately 53 million shares outstanding.

For anyone truly interested in NNVC, I recommend skipping the hyperbole of some and do go read the 10Q. I usually find such things through links on NNVC's web site or by using sites like OTCmarkets, Yahoo Finance, etc. In the 10Q one will read about corporate history, company developments, share structure, financials, major corporate affiliations, etc. Also, there are lots of warnings proffered by management concerning potential risks.

Read it and enjoy. You may want to buy.